Hinge Bio

Burlingame, United States

Hinge Bio specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies.

$30.0M raised

Jan 2025

Series A

Top Investors

National Science FoundationPoint72Agent CapitalInVivium CapitalLightswitch Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Hinge Bio raised?

Hinge Bio has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.

Who are Hinge Bio's investors?

Hinge Bio's investors include National Science Foundation, Point72, Agent Capital, InVivium Capital, Lightswitch Capital.

Where is Hinge Bio headquartered?

Hinge Bio is headquartered in Burlingame, United States.

What does Hinge Bio do?

Hinge Bio specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies.

What stage is Hinge Bio at?

Hinge Bio is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 15, 2025.

MLA

"Hinge Bio — Funding & Investors." VCBacked, January 15, 2025, https://www.vcbacked.co/company/hinge-bio. Accessed June 4, 2026.

APA

VCBacked. (2025). Hinge Bio — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/hinge-bio

Wikipedia (cite web)

{{cite web |title=Hinge Bio — Funding & Investors |url=https://www.vcbacked.co/company/hinge-bio |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 15, 2025.